Anti-S serologies after vaccination or SARS-CoV-2 infection. Anti-S serologies in 16 patients who had available titers at several time points after SARS-CoV-2 infection or vaccination during the study period. The y-axis for P13 and P16 is shown using a different scale, given the high anti-S titers relative to that of other patients. P16 received tixagevimab/cilgavimab before serologies were drawn.